Álvaro Pascual-rekin lankidetzan egindako argitalpenak (8)

2018

  1. Comparison of Predictors and Mortality between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae

    Infection Control and Hospital Epidemiology, Vol. 39, Núm. 6, pp. 660-667

  2. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae

    International Journal of Antimicrobial Agents, Vol. 52, Núm. 5, pp. 577-585

2017

  1. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae

    The Journal of antimicrobial chemotherapy, Vol. 72, Núm. 3, pp. 906-913

  2. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

    The Lancet Infectious Diseases, Vol. 17, Núm. 7, pp. 726-734

  3. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study

    International Journal of Antimicrobial Agents, Vol. 50, Núm. 5, pp. 664-672

2016

  1. A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae

    Mayo Clinic Proceedings, Vol. 91, Núm. 10, pp. 1362-1371

  2. A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing enterobacteriaceae

    Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 7, pp. 4159-4169

  3. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: A multinational pre-registered cohort study

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 6, pp. 1672-1680